Document Detail

The effect of a large regional health plan's value-based insurance design program on statin use.
MedLine Citation:
PMID:  23047782     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Cost-sharing requirements employed by health insurers to discourage the unnecessary use of medications may lead to underutilization of recommended treatment regimens and suboptimal quality of care. Value-based insurance design (VBID) programs seek to address these problems by lowering copayments to promote adherence to "high-value" medications that have been proven to be clinically beneficial. VBID evaluations to date have focused on programs implemented by self-insured employers. This study is among the first to assess the VBID program of a health plan.
METHODS: We examined a VBID program for statins implemented by a large regional health plan in 2008 and assessed its effect on medication adherence. Copayments on VBID brand statins were reduced by 42.9% for employer-sponsored plans (the treatment group) and increased by 16.7% for state-sponsored plans (the control group) between the preintervention and postintervention periods. Propensity score weights were used to balance the treatment and control groups on observed characteristics. We evaluated the impact of the VBID program on adherence using an econometric model with a difference-in-difference design.
RESULTS: Medication adherence increased 2.7 percentage points (P=0.033) among VBID brand statin users in the treatment group relative to the control group. With a baseline adherence rate of 77.6%, nonadherence was reduced by 11.9%.
CONCLUSIONS: Copayment reductions on selected statin medications contributed to improvements in adherence. As one of the first studies to evaluate a health plan's VBID program, our findings demonstrate that insurer-based VBID programs may yield results similar to those achieved by employer-based programs.
Matthew B Frank; A Mark Fendrick; Yulei He; Arthur Zbrozek; Norma Holtz; Simon Leung; Michael E Chernew
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Medical care     Volume:  50     ISSN:  1537-1948     ISO Abbreviation:  Med Care     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-10-10     Completed Date:  2013-01-07     Revised Date:  2014-04-08    
Medline Journal Info:
Nlm Unique ID:  0230027     Medline TA:  Med Care     Country:  United States    
Other Details:
Languages:  eng     Pagination:  934-9     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cost Sharing / economics*,  methods*
Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage*,  economics*
Insurance Carriers / economics*
Medication Adherence / statistics & numerical data
Middle Aged
Propensity Score
United States
Reg. No./Substance:
0/Hydroxymethylglutaryl-CoA Reductase Inhibitors

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Economic differences in direct and indirect costs between people with epilepsy and without epilepsy.
Next Document:  Association Between the Commercial Characteristics of Psychotropic Drugs and Their Off-label Use.